Inhibition of DEF‐p65 Interactions as a Potential Avenue to Suppress Tumor Growth in Pancreatic Cancer

Abstract

AbstractThe limited success of current targeted therapies for pancreatic cancer underscores an urgent demand for novel treatment modalities. The challenge in mitigating this malignancy can be attributed to the digestive organ expansion factor (DEF), a pivotal yet underexplored factor in pancreatic tumorigenesis. The study uses a blend of in vitro and in vivo approaches, complemented by the theoretical analyses, to propose DEF as a promising anti‐tumor target. Analysis of clinical samples reveals that high expression of DEF is correlated with diminished survival in pancreatic cancer patients. Crucially, the depletion of DEF significantly impedes tumor growth. The study further discovers that DEF binds to p65, shielding it from degradation mediated by the ubiquitin‐proteasome pathway in cancer cells. Based on these findings and computational approaches, the study formulates a DEF‐mimicking peptide, peptide‐031, designed to disrupt the DEF‐p65 interaction. The effectiveness of peptide‐031 in inhibiting tumor proliferation has been demonstrated both in vitro and in vivo. This study unveils the oncogenic role of DEF while highlighting its prognostic value and therapeutic potential in pancreatic cancer. In addition, peptide‐031 is a promising therapeutic agent with potent anti‐tumor effects.